Holen Sie sich die Stockscreener-App
8.53
2.16%
0.18
Handel nachbörslich:
8.49
-0.04
-0.47%
Schlusskurs vom Vortag:
$8.35
Offen:
$8.4
24-Stunden-Volumen:
3.71M
Relative Volume:
0.98
Marktkapitalisierung:
$1.79B
Einnahmen:
$503.49M
Nettoeinkommen (Verlust:
$-53.47M
KGV:
-32.81
EPS:
-0.26
Netto-Cashflow:
$-26.89M
1W Leistung:
-0.81%
1M Leistung:
-2.63%
6M Leistung:
-3.29%
1J Leistung:
+8.11%
1-Tages-Spanne:
$8.395
$8.64
1-Wochen-Bereich:
$8.08
$8.65
52-Wochen-Spanne:
$6.015
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
8.53 | 1.72B | 503.49M | -53.47M | -26.89M | -0.26 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst (BCRX) Q2 Revenue Jumps 50% - AOL.com
Are Options Traders Betting on a Big Move in BCRX Stock? - Nasdaq
Will BioCryst Pharmaceuticals Inc. benefit from rising consumer demandStock Picks with Accelerated Return - newsyoung.net
BioCryst’s Chief R&D Officer Resigns Amid CEO Decision - The Globe and Mail
BioCryst Announces Departure of Dr. Helen Thackray - GlobeNewswire
BioCryst Announces Departure of Dr. Helen Thackray | BCRX Stock News - GuruFocus
BioCryst’s chief R&D officer to depart for CEO role elsewhere By Investing.com - Investing.com Australia
BioCryst's R&D Chief Departs Following CEO Race: What This Means for ORLADEYO and 2 Pipeline Drugs - Stock Titan
BioCryst’s BCX17725: A Promising Step Forward in Treating Netherton Syndrome - TipRanks
BioCryst Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year - simplywall.st
BioCryst (BCRX) Gets a Buy from RBC Capital - The Globe and Mail
BioCryst Pharmaceuticals 2025 Q2 Earnings Record Net Income Surges 140% - AInvest
Biocryst Pharmaceuticals shares rise 1.20% premarket after reporting inducement grants under Nasdaq listing. - AInvest
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
BioCryst reports inducement grants under Nasdaq listing rule - TipRanks
BioCryst Pharmaceuticals Receives Buy Rating from RBC Capital Analyst Brian Abrahams - AInvest
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 563 - GuruFocus
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BioCryst Pharmaceuticals grants 36,700 shares of stock options and RSUs to new employees. - AInvest
BioCryst Awards Massive Stock Package: 10 New Hires Get 126,450 Shares in Options and RSUs - Stock Titan
BioCryst’s Earnings Call Highlights Strong Growth and Strategic Moves - TipRanks
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
BioCryst’s Orladeyo: Strong Market Outlook and Strategic Expansion Drive Buy Rating - TipRanks
BioCryst Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
BioCryst: Q2 Earnings Snapshot - New Haven Register
BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... - Yahoo Finance
BioCryst Pharmaceuticals Reports Record Q2 2025 Results - TipRanks
BioCryst Pharmaceuticals: A Strategic Blueprint for $1 Billion in ORLADEYO Revenue by 2027 - AInvest
BioCryst Pharmaceuticals' Q2 2025: Unpacking Contradictions in ORLADEYO Demand, Market Share, and Financial Metrics - AInvest
BioCryst Pharmaceuticals, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:BCRX) - Seeking Alpha
Transcript : BioCryst Pharmaceuticals, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
BioCryst Eyes Strengthening Pipeline After Upbeat Q2 Earnings: Retail Thinks Fair Valuation For Stock Is Double The Current Level - Stocktwits
BioCryst Pharmaceuticals Soars 15.35% on Strong Earnings - AInvest
Earnings call transcript: BioCryst Q2 2025 sees strong earnings beat, shares surge - Investing.com
BioCryst Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
BioCryst Pharmaceuticals Reports Impressive Q2 EarningsNews and Statistics - IndexBox
BioCryst Keeps Momentum With Strong ORLADEYO Sales And Rising Profits - Finimize
BioCryst Pharma soars 6.4% as Q2 results crush expectations By Investing.com - Investing.com Nigeria
BioCryst Pharma soars 6.4% as Q2 results crush expectations - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates - Investing.com
BioCryst Q2 2025 slides: ORLADEYO demand surges, profitability accelerates By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
BioCryst Pharmaceuticals' Q2 Adjusted Earnings Swings to Profit, Revenue Rises; Maintains 2025 Guidance - MarketScreener
BioCryst Pharmaceuticals: A High-Conviction Biotech Play with a Defensible Moat in Rare Disease Innovation - AInvest
BioCryst Reports Strong Q2 2025 Financial Performance - TipRanks
Is This the Dip to Buy in BioCryst Pharmaceuticals Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
BioCryst (BCRX) Q2 Revenue Jumps 50% - The Motley Fool
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Reports Q2 Revenue $163.4M, vs. FactSet Est of $149.8M - MarketScreener
Earnings Flash (BCRX) BioCryst Pharmaceuticals, Inc. Posts Q2 Adjusted EPS $0.15 per Share, vs. FactSet Est of $0.01 - MarketScreener
BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Is it the right time to buy BioCryst Pharmaceuticals Inc. stockTrack high-yield stocks before they peak - Jammu Links News
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):